US EditionSafety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhD
Summary by neurologylive.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Safety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhD
The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]
Benefits and Risks of New Tests for Alzheimer’s Disease
Benefits and Risks of New Tests for Alzheimer’s Disease Alzheimer disease (AD) is the most common form of dementia with a prevalence of approximately 10% in people aged 65 years and older.1 Current methods used to aid in the diagnosis of AD, such as cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) scanning of specific AD biomarkers, have been instrumental in reducing misdiagnosis and guiding management of patients with mi…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
